Literature DB >> 10729989

Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update.

R Yang1, Z C Han.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) is a disorder characterized by platelet destruction caused by an antiplatelet autoantibody that results in platelet phagocytosis via the reticuloendothelial system. The condition will become chronic in 10% to 20% of children with ITP and almost all adult ITP patients. The expert panel established in 1994 by the American Society of Hematology extensively reviewed ITP-related articles before 1995 and published practice guidelines. This publication is of great help in regard to research and management of ITP. However, the pathogenesis of chronic ITP has not been fully elucidated, and its management is primarily empirical. This review focuses mainly on the articles published after 1995, including some experiences in China.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729989

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  12 in total

1.  Bmi-1 regulates autoreactive CD4+ T cell survival in immune thrombocytopenia patients.

Authors:  Li Ma; Zeping Zhou; Donglei Zhang; Hongmei Wang; Huiyuan Li; Feng Xue; Renchi Yang
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

2.  [Splenectomy for thrombocytopenic purpura. Retrospective analysis of the postoperative course].

Authors:  K Beseoglu; U Germing; W Gross-Weege
Journal:  Chirurg       Date:  2005-08       Impact factor: 0.955

3.  B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy.

Authors:  Paola Giordano; Simona Cascioli; Giuseppe Lassandro; Valentina Marcellini; Fabio Cardinale; Federica Valente; Franco Locatelli; Rita Carsetti
Journal:  Pediatr Res       Date:  2015-10-22       Impact factor: 3.756

4.  CD72 polymorphism associated with child-onset of idiopathic thrombocytopenic purpura in Chinese patients.

Authors:  Jianhui Xu; Shihong Lu; Jie Tao; Zeping Zhou; Zhenping Chen; Ying Huang; Renchi Yang
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

5.  Decreased DNA methyltransferase 3A and 3B mRNA expression in peripheral blood mononuclear cells and increased plasma SAH concentration in adult patients with idiopathic thrombocytopenic purpura.

Authors:  Jie Tao; Ming Yang; Zhong Chen; Ying Huang; Qinjun Zhao; Jianhui Xu; He Ren; Hui Zhao; Zhenping Chen; Qian Ren; Renchi Yang
Journal:  J Clin Immunol       Date:  2008-08-06       Impact factor: 8.317

6.  Single nucleotide polymorphism in DNMT3B promoter and the risk for idiopathic thrombocytopenic purpura in Chinese population.

Authors:  Zhenping Chen; Zeping Zhou; Xiaoli Chen; Jianhui Xu; Aijuan Liu; Weiting Du; Dongsheng Gu; Jing Ge; Zhenxing Guo; Xiaoyan Wang; Xunwei Dong; Qian Ren; Renchi Yang
Journal:  J Clin Immunol       Date:  2008-04-25       Impact factor: 8.317

7.  Should we routinely transfuse platelet for immune thrombocytopenia patients with platelet count less than 10 × 10⁹/L who underwent laparoscopic splenectomy?

Authors:  Yunqiang Cai; Xubao Liu; Bing Peng
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

8.  Prediction of response to splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  A Shojaiefard; S A Mousavi; S H Faghihi; S Abdollahzade
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

9.  The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.

Authors:  Semir Pasa; Abdullah Altintas; Timucin Cil; Ramazan Danis; Orhan Ayyildiz
Journal:  J Thromb Thrombolysis       Date:  2008-03-03       Impact factor: 2.300

10.  Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.

Authors:  Jaime Garcia-Chavez; Abraham Majluf-Cruz; Laura Montiel-Cervantes; Miriam García-Ruiz Esparza; Jorge Vela-Ojeda
Journal:  Ann Hematol       Date:  2007-09-14       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.